Video: Lamellar's McLean Talks R&D plans and early-stage CF therapy
This article was originally published in Scrip
Mike Ward, global director of content for Informa Pharma Insights, chats to Lamellar Biomedical ltd.'s CEO Dr. Alec McLean at the recent BIO-Europe partnering meeting in Munich, Germany, about the firm's R&D plans for recently raised funds and progress of Lamellar's cystic fibrosis program.
You may also be interested in...
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.